Last reviewed · How we verify
alendronate sodium vitamin D3 tablets
At a glance
| Generic name | alendronate sodium vitamin D3 tablets |
|---|---|
| Sponsor | Peking Union Medical College Hospital |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Bone Turnover Markers and Treatment Efficacy in Postmenopausal Osteoporosis (NA)
- Effect of Anti-osteoporotic Medications on Nonalcoholic Fatty Liver Disease (PHASE4)
- Alendronate in an Weekly Effervescent Tablet Formulation Following Denosumab Discontinuation
- A Study to Evaluate the Safety, Tolerability, and Efficacy of an Investigational Drug and Dietary Supplement in Men and Postmenopausal Women With Osteoporosis (0217A-227) (PHASE3)
- A Study to Evaluate Alendronate Sodium /Vitamin D3 Combination Tablets(FOSAMAX PLUS) Versus Calcitriol in the Treatment of Osteoporosis in Postmenopausal Women in China (MK-0217A-264) (PHASE4)
- A Study to Test the Effect of MK0217A on Vitamin D Inadequacy in Postmenopausal Women With Osteoporosis (0217A-262) (PHASE3)
- Efficacy and Safety Study of Fosamax Plus D in Postmenopausal Women With Osteoporosis (0217A-263) (PHASE4)
- Study of MK-217A/Alendronate Sodium 70-mg/Vitamin D3 5600 IU Combination Tablet (MK-0217A-329) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: